Alliance Boots
This article was originally published in The Rose Sheet
Executive Summary
Firm releases pro forma financial statement detailing the results of fiscal year 2006 (ended March 31) "as if the two former groups" that merged in July 2006 to form Alliance Boots - Boots Group and Alliance UniChem - "had always been combined." The company's revenue increased 2.9% to $13.9 bil. (£7.03 bil.) for the year, which "demonstrates that the Group is well positioned following the merger," CEO Richard Baker said, noting that the firm experienced "good trading" in its retail and wholesale divisions. "We are confident about the opportunities both to strengthen our existing businesses and to expand into new territories. We have made good progress so far but there is much to do," the exec remarked. Meanwhile, Alliance Boots recommended in late April that its shareholders accept a $22 bil. acquisition bid from AB Acquisitions (1"The Rose Sheet" April 30, 2007, p. 8)...
You may also be interested in...
Alliance Boots Mulls New Ownership Following $22 Billion Bid
Global growth of Alliance Boots, the UK's largest pharmacy-led health and beauty retailer, will be accelerated under new ownership, according to AB Acquisitions, which has made a $22 billion (?11.1 billion) bid for the firm
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.